MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Russian Bear who wrote (982)	5/14/1998 2:35:00 PM
From: bocaburgerman	of 1826

May 14, 1998/FOOLWIRE/ -- MGI Pharmaceuticals (Nasdaq: MOGN) gave back $2 1/16 to $10 3/4 after the company's 65% advance yesterday that came about due to management remarks at its annual meeting about its anticancer drug, MG 114. Chief Operating Officer James V. Adam told shareholders that the company believes MG 114 is "... just as promising, and just as unproven, as other cancer therapies recently discussed in the media." Adam is talking about EntreMed's (Nasdaq: ENMD) anticancer drugs, which were highlighted in a New York Times piece that drove its stock up dramatically in one day.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next